Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF) (COMET)
COMET: Correlating Outcomes With Biochemical Markers to Estimate Time-progression in IPF. A Prospective, Multi-Center, Longitudinal Follow up Study of Subjects With Idiopathic Pulmonary Fibrosis
Study purpose:
The disease course of idiopathic pulmonary fibrosis (IPF) is variable. During the course of the disease some patients will get better, some will stay the same, and others will get worse. Currently doctors do not have any way to predict an individual patients disease course. The purpose of this study is to determine if 'biomarkers' such as proteins or genes isolated at the time of diagnosis can be used to predict the disease course. These 'biomarkers' will be obtained from samples of blood, from a procedure call a bronchoscopy, and in some patients from extra tissue obtained by a surgical lung biopsy.
연구 개요
상태
정황
상세 설명
The objectives of this study are as follows:
Specific Aim 1: Assemble a network of clinical centers to procure biologic samples from subjects with recently diagnosed IPF and follow these subjects for at least 48 weeks. Specific Aim 2: Correlate and integrate biologically plausible biomarkers of disease activity obtained from multiple compartments (SLB, BAL, TBB, blood) from the same subject with longitudinal measures of disease progression (change in forced vital capacity, change in diffusion capacity for carbon monoxide, acute exacerbation of pulmonary fibrosis, and death).
General Study Design This study will take place in two phases. During the first phase of the study we will identify and collect baseline specimens from subjects with either suspected or recently diagnosed (within 48 months) IPF. During the second phase of the study subjects with IPF will be followed from between 48 and 80 weeks. Subjects will be followed until the end of study (2 year grant award) or until they meet any part of a composite endpoint (death, acute exacerbation of IPF, relative decline in FVC of at least 10% or DLCO of 15%). This is a prospective cohort study. There is no treatment prescribed or studied as part of this prospective cohort study. Subjects are able to utilize any treatments prescribed by their physician, including participation in clinical trials as long as they are able to comply with the follow up schedule in this study.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
California
-
Los Angeles, California, 미국, 90095
- University of California, Los Angeles
-
San Francisco, California, 미국, 94143
- University of California, San Francisco
-
-
Colorado
-
Denver, Colorado, 미국, 80206
- National Jewish Medical and Research Center
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- University of Chicago
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- University of Michigan
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19140
- Temple University
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02903
- Brown University
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232
- Vanderbilt University
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Suspected or confirmed diagnosis of IPF
- Age 35 - 80 years inclusive
- Ability to understand and provide informed consent
Exclusion Criteria:
- Confirmed diagnosis of IPF at the study center more than 4 years prior to screening
- Environmental exposure (occupational, environmental, drug, etc) felt by the principal investigator (PI) to be the etiology of the interstitial disease
- Diagnosis of collagen-vascular conditions (according to the published American College of Rheumatology criteria)
- Forced expiratory volume in 1 second (FEV1)/FVC ratio < 0.60 at screening (postbronchodilator)
- Significant bronchodilator response on screening spirometry, defined as a change in FEV1 ≥ 12% and absolute change > 200 mL OR change in FVC ≥ 12% and absolute change > 200 mL
- Evidence of active infection at screening
- Listed for lung transplantation at time of screening
- Unstable or deteriorating cardiac disease at screening
- Myocardial infarction, coronary artery bypass, or angioplasty within 6 months of screening
- Unstable angina pectoris or congestive heart failure requiring hospitalization within 6 months of screening
- Uncontrolled arrhythmia at screening
- Severe uncontrolled hypertension at screening
- Known HIV or hepatitis C at screening
- Known cirrhosis or chronic active hepatitis at screening
- Active substance and/or alcohol abuse at screening
- Subjects who are pregnant or breastfeeding at screening
- Women of childbearing potential who are not using a medically approved means of contraception at screening
- Known bleeding abnormality that would preclude the performance of transbronchial lung biopsy
- Prothrombin time, INR > 1.5, Partial Thromboplastin Time (PTT) > 45 at time of screening, platelets < 100,000/mm3
- Any condition other than IPF that, in the opinion of the site PI, is likely to result in the death of the subject within the next year
- Any condition that, in the judgment of the site PI, might cause participation in this study to be detrimental to the subject or that the site PI deems makes the subject a poor candidate
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
Confirmed Diagnosis of IPF
Subjects in this cohort will continue beyond the screening visit(s) for longitudinal follow up visits for a minimum of 48 weeks and maximum of 80 weeks.
|
|
No diagnosis of IPF
Subjects that complete screening visits and do not obtain a confirmed diagnosis of IPF will conclude the study at screening, at the time point where IPF is ruled out as a diagnosis.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
The primary outcome is progression free survival as determined by time until any of: death, acute exacerbation of IPF, relative change in FVC (liters) of at least 10% or DLCO (ml/min/mmHg) of 15%.
기간: Follow up visits after baseline, every 16 weeks for minimum of 40 weeks and maximum of 80 weeks
|
Follow up visits after baseline, every 16 weeks for minimum of 40 weeks and maximum of 80 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Galen B Toews, MD, University of Michigan
- 수석 연구원: Kevin R Flaherty, MD, MS, University of Michigan
- 연구 책임자: Herbert Reynolds, MD, National Heart, Lung and Blood Institute, Division of Lung Sciences, National Institute of Health
- 수석 연구원: Fernando J Martinez, MD,MS, University of Michigan
간행물 및 유용한 링크
일반 간행물
- Allen RJ, Stockwell A, Oldham JM, Guillen-Guio B, Schwartz DA, Maher TM, Flores C, Noth I, Yaspan BL, Jenkins RG, Wain LV; International IPF Genetics Consortium. Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. Thorax. 2022 Aug;77(8):829-833. doi: 10.1136/thoraxjnl-2021-218577. Epub 2022 Jun 10.
- Whalen W, Buyukozkan M, Moore B, Moon JS, Dela Cruz CS, Martinez FJ, Choi AMK, Krumsiek J, Stout-Delgado H, Cho SJ. Association of circulating cell-free double-stranded DNA and metabolic derangements in idiopathic pulmonary fibrosis. Thorax. 2022 Feb;77(2):186-190. doi: 10.1136/thoraxjnl-2021-217315. Epub 2021 Sep 14.
- Galli JA, Panetta NL, Gaeckle N, Martinez FJ, Moore B, Moore T, Courey A, Flaherty K, Criner GJ; COMET investigators. Pneumothorax After Transbronchial Biopsy in Pulmonary Fibrosis: Lessons from the Multicenter COMET Trial. Lung. 2017 Oct;195(5):537-543. doi: 10.1007/s00408-017-0028-z. Epub 2017 Jun 16.
- Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, Moore BB, White ES, Flaherty KR, Huffnagle GB, Martinez FJ; COMET Investigators. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014 Jul;2(7):548-56. doi: 10.1016/S2213-2600(14)70069-4. Epub 2014 Apr 21. Erratum In: Lancet Respir Med. 2014 Aug;2(8):e14.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
특발성 폐 섬유증에 대한 임상 시험
-
University of Colorado, Denver모집하지 않고 적극적으로단심실 | 폐 혈관 저항 이상 | 대사체학 | 우수한 Cavo-Pulmonary 문합 | 엔도텔린미국